Oncogenic Signaling with Larotrectinib | LOXO-195 for Those Progressed on TRK-Inhibitor

Oncogenic Signaling with Larotrectinib | LOXO-195 for Those Progressed on TRK-Inhibitor

Annual-Meeting

1 year
139 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Scott Z. Fields, MD, Bayer Pharmaceuticals explains Oncogenic Signaling with Larotrectinib | LOXO-195 for Those Progressed on TRK-Inhibitor at Annual Meeting 2018

 

 

 

 

oncogenic signaling, larotrectinib & #124, loxo-195, trk-inhibitor, annual meeting 2018, bayer pharmaceuticals

Up Next Autoplay